Reduction of liver-derived circulating mutant and wild type amyloidgenic TTR protein using patisiran, which acts by a similar mechanism, has been shown to improve the polyneuropathy disease manifestations of hATTR amyloidosis [13]. Here, TTR is linked to amyloidosis.